1st Edition

MAY 5 2023

MILAN, ITALY & ONLINE

President of the conference: ARSELA PRELAJ

AI methodologies have been applied to medical research for years, and has recently made an impactful entrance in oncology more specifically.
AI broadly speaking consists in a set of techniques allowing computers to emulate human intelligence, employing algorithms created for the analyses and the design of either predictions or conclusions based on the nalysis of big datasets.
The latter is especially important for cancer research considering the critical mass of data available for analysis and that standard analysis methods fail to exploit to its fullest potential.
This is particularly the case for multiomics data, with their high variation in nature, format or storage. The proper and effective and integration of these novel methodologies into the standards of clinical – but also basic and translational – research could prove to be an important leap forward for oncology research.

Hence, this event will have two core training objectives:
– The first will be to ease the clinical and research community into the mindset of AI methodologies themselves, as it has been applied to the medical field for years now, for instance in designing medical devices, yet is still misunderstood or not known to its full potential – from a general overview of the most frequently used ML/DL methods and Explainable AI to a deep dive in novel data platforms and repository structures integrating these approaches in their design. This will allow clinicians to identify the value of AI models for their trials and studies, making the volume of patient- and tumor-related data valuable and more fully exploitable; as well as biologists to increase the playing field in tumor biology to discover new biomarkers and mechanisms.
– The second main endpoint will be to demonstrate not only the possibilities offered by the inclusion of AI models in standard practice, but really to present some concrete and innovative activities where they are already being successfully implemented.
The focus is to demonstrate in particular the value of AI for both its predictive power and for the possibilities it opens up for the discovery of both new biomarkers and of new molecules targeting specific tumors. In particular, one section will be focused on the translational field and the synergy between AI-powered multiomic data analysis and clinical research, with regards to cancer immunotherapy. As the AI research field is evolving at a rapid pace, the event will be topped off by a session offering perspectives already going beyond the current state of the art and providing insights into the AI of tomorrow – how it could be involved as full-fledged actor in clinical decision-making, all the way to the field of quantum sciences.
The event is set to be a full-day program. The speakers will have a diverse background to reflect the spectrum of AI research (and beyond), from AI engineering experts, to clinicians and translational researchers, and hybrid figures such as clinical AI specialists. The attendance is expected to mirror this variety, along with participants with a more specific background in imaging and pathology.

FACULTY

AGNELLI LUCA Milan, Italy
AMBROSINI EMILIA Milan, Italy
AULETTA PIETRO Milan, Italy
BIASIN ELISABETTA Leuven, Belgium
BOERI MATTIA Milan, Italy
CASTELO-BRANCO LUÎS Lugano, Switzerland
CICCHETTI ALESSANDRO Milan, Italy
DAMIAN SILVIA Milan, Italy
DE BRAUD FILIPPO Milan, Italy
DE TOMA ALESSANDRO Varese, Italy
DELLA CORTE CARMINIA MARIA Naples, Italy
DOLEZAL JAMES Chicago, USA
FERRARA ROBERTO Milan, Italy
GAGLIARDI LAURA Chicago, USA
GANZINELLI MONICA Milan, Italy
GARASSINO MARINA CHIARA Chicago, USA
GENOVA CARLO Genoa, Italy
GROSSMAN ROBERT L. Chicago, USA
KATHER JAKOB NIKOLAS Dresden, Germany
KOSTA SOKOL Copenaghen, Denmark
LO RUSSO GIUSEPPE Milan, Italy
MAZZEO LAURA Milan, Italy
MISKOVIC VANJA Milan, Italy
MONZANI DARIO Palermo, Italy
PASTORINO UGO Milan, Italy
PEARSON ALEXANDER T. Chicago, USA
PEDROCCHI ALESSANDRA LG Milan, Italy
PÉREZ-LOPEZ RAQUEL Barcelona, Spain
PRELAJ ARSELA Milan, Italy
PROTO CLAUDIA Milan, Italy
SHAH SOHRAB New York, USA
SIGNORELLI DIEGO Milan, Italy
TROVÒ FRANCESCO VMilan, Italy
VIBERT JULIEN Paris, France
VINGIANI ANDREA Milan, Italy
VISCARDI GIUSEPPE Naples, Italy

SCIENTIFIC COMMITEE

PRESIDENT OF THE CONFERENCE

Arsela Prelaj, MD, PhD Candidate Medical Oncologist and PhD Candidate in Bioengineering and Artificial Intelligence Politecnico di Milano;
Thoracic Oncology Unit, Medical Oncology Department 1 Fondazione IRCCS stituto Nazionale Tumori, Milan (Italy);
Esmo Working Group Member of Real World Data and Digital Health

SCIENTIFIC SECRETARIAT

  • Claudia Giani
  • Laura Mazzeo
  • Vanja Miskovic
  • Leonardo Provenzano
  • Giovanni Scoazec
  • Andrea Spagnoletti
  • Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy)

VENUE
Aula Magna Fondazione IRCCS Istituto Nazionale Tumori
Via Giacomo Venezian, 1 – Milan (Italy)

VIRTUAL CONFERENCE
www.events-fad.com

CME CREDITS
CME accreditation (valid for Italian participants only) for: PHYSICIAN, PHARMACIST, BIOLOGIST, NURSE CME credits: 4,2 – ID event: 372599 (in presence) CME credits: 9 – ID event: 372613 (online) Italian CME credits will be granted to those participants who attend at least 90% of scientific works, fill in the questionnaire assessment of perceived quality and duly fill in the evaluation questionnaires answering correctly 75% of the questions.

OFFICIAL LANGUAGE
The official language is English

OFFICIAL TIME
The official Time is Central European Summer Time (CEST), UTC +2